Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster to be given at the ISPOR 2024; May 8, 2024. Atlanta, GA.
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled burden of RSV in adults aged 50-59 years with chronic cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled impact of adjuvanted RSVPREF3 vaccination on RSV-related health outcomes in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.
Grace M, Costello J, Colosia A, Wolowacz S, Ghaswalla P, Panozzo CA, Moore P. Economic and HRQoL burden in adults with RSV: a systematic literature review. Poster presented at the Communicable Diseases & Immunisation Conference 2023; June 20, 2023. Perth, Australia. Previously presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW).
Grace M, Costello J, Colosia A, Wolowacz S, Panozzo CA, Ghaswalla P. Economic and health-related quality of life burden in adults with RSV: a systematic literature review and gap analysis. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.
Grace M, Colosia A, Wolowacz S, Panozzo C, Ghaswalla P. Economic burden of respiratory syncytial virus infection in adults: a systematic literature review. J Med Econ. 2023;26(1):742-59. doi: 10.1080/13696998.2023.2213125